ArticleThe Journal of international medical research2026
Cytomegalovirus prophylaxis using low-dose and ultra-low-dose valganciclovir for patients who have undergone allogeneic hematopoietic stem cell transplantation: A retrospective study.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveCytomegalovirus reactivation is a clinically significant complication after allogeneic hematopoietic stem cell transplantation. Valganciclovir is commonly used for cytomegalovirus prophylaxis; however, the optimal dosing strategy remains unclear. This study compared the efficacy and safety of ultra-low-dose valganciclovir (450 mg every other day) and low-dose valganciclovir (450 mg daily) in preventing cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.MethodsWe retrospectively reviewed adult patients who underwent allogeneic hematopoietic stem cell transplantation from January 2020 to December 2023. Individuals receiving low-dose (n = 31) or ultra-low-dose (n = 35) valganciclovir as cytomegalovirus prophylaxis were included. Cytomegalovirus DNAemia was evaluated within the first 14 weeks and then at 14-28 weeks after transplantation. Cytomegalovirus disease, acute graft-versus-host disease, survival outcomes, and hematologic toxicities were also assessed.ResultsThe prevalence of early cytomegalovirus reactivation was 13.8% in the low-dose group and 20.0% in the ultra-low-dose group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.